Skip to main content

Table 3 Change in variables in obese with NAFLD children treated with GH vs control group for 3 months

From: Effect of growth hormone therapy on liver enzyme and other cardiometabolic risk factors in boys with obesity and nonalcoholic fatty liver disease

Variable rhGH group
(n = 22)
control group
(n = 22)
p value
BMI SDS 2.37 ± 0.69 2.66 ± 0.54 0.138
IGF-1(ng/ml) 473.36 ± 159.12 355.86 ± 126.98 0.01*
CRP(mg/L) 1.24 ± 0.80 2.07 ± 1.14 0.008*
ALT(U/L) 18.25(13.50,27.75) 21.00(16.75, 42.25) 0.113▲
AST(U/L) 21.50(19.88,28.75) 23.00(20.00, 30.50) 0.430▲
GGT(U/L) 14.00(12.75,17.75) 24.00(20.00, 33.25)  < 0.001*▲
TC(mmol/L) 3.99 ± 0.59 4.15 ± 0.76 0.432
HDL-C (mmol/L) 1.41 ± 0.30 1.12 ± 0.20 0.001*
LDL-C (mmol/L) 2.17 ± 0.42 2.49 ± 0.53 0.033*
TG(mmol/L) 0.90(0.71, 1.52) 1.05(0.82, 1.38) 0.578#
UA(μmol/L) 423.96 ± 97.51 376.64 ± 78.65 0.084
Insulin(uIU/mL) 31.16(21.28,36.75) 17.04(14.43, 28.46) 0.086#
FBG(mmol/L) 5.34 ± 0.31 5.25 ± 0.40 0.393
HOMA-IR 7.34(5.16, 8.76) 3.99(3.02, 6.94) 0.078#
HbA1c (%) 5.62 ± 0.35 5.62 ± 0.30 1#
  1. # p value reported for log transformed values, but values in the table represent as the median (interquartile range) ▲Mann–Whitney U test
  2. * p < 0.05
  3. Abbreviations: BMI SDS Body mass index standard deviation scores, IGF-1 Insulin-like growth factor 1, CRP C reactive protein, ALT Alanine aminotransferase, AST Aspartate aminotransferase, GGT Gamma-glutamyl transferase, GH Growth hormone, TC Total cholesterol, HDL-C High density lipoprotein cholesterol, LDL-C Low density lipoprotein cholesterol, TG Triglycerides, UA Uric acid, FBG Fasting blood glucose, HOMA-IR Homeostasis model assessment of IR, HbA1c Glycosylated haemoglobin